Analyst Price Targets — TVTX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| April 14, 2026 3:15 pm | — | Piper Sandler | $49.00 | $41.11 | TheFly | Travere Therapeutics upgraded to Overweight from Neutral at Piper Sandler |
| April 14, 2026 11:34 am | — | Guggenheim | $54.00 | $30.70 | TheFly | Travere Therapeutics price target raised to $54 from $49 at Guggenheim |
| January 14, 2026 11:48 am | Vamil Divan | Guggenheim | $49.00 | $28.39 | StreetInsider | Guggenheim Reiterates Buy rating and Best Idea on Travere Therapeutics (TVTX) |
| September 10, 2025 2:48 pm | Maury Raycroft | Jefferies | $35.00 | $27.31 | TheFly | AdCom cancellation 'clear positive' for Travere Therapeutics, says Jefferies |
| October 31, 2024 8:21 pm | Liisa Bayko | Evercore ISI | $33.00 | $17.50 | StreetInsider | Travere Therapeutics (TVTX) PT Raised to $33 at Evercore ISI |
| October 21, 2024 5:38 am | Mohit Bansal | Wells Fargo | $27.00 | $17.87 | StreetInsider | Wells Fargo Upgrades Travere Therapeutics (TVTX) to Overweight |
| October 10, 2024 9:24 am | Liisa Bayko | Evercore ISI | $30.00 | $18.07 | TheFly | Travere Therapeutics price target raised to $30 from $12 at Evercore ISI |
| October 9, 2024 6:57 am | Jason Zemansky | Bank of America Securities | $20.00 | $15.21 | TheFly | Travere Therapeutics price target raised to $20 from $18 at BofA |
| October 1, 2024 5:38 am | Carter Gould | Barclays | $18.00 | $13.99 | TheFly | Travere Therapeutics price target raised to $18 from $14 at Barclays |
| September 27, 2024 6:42 am | Vamil Divan | Guggenheim | $23.00 | $15.04 | TheFly | Travere Therapeutics price target lowered to $23 from $25 at Guggenheim |
Latest News for TVTX
Travere Therapeutics, Inc. (NASDAQ: TVTX - Get Free Report) CAO Sandra Calvin sold 21,977 shares of the firm's stock in a transaction on Tuesday, April 14th. The stock was sold at an average price of $41.07, for a total value of $902,595.39. Following the sale, the chief accounting officer owned 42,353 shares in the company, valued
Travere Therapeutics, Inc. (NASDAQ: TVTX - Get Free Report) Director Roy Baynes sold 32,750 shares of the firm's stock in a transaction that occurred on Tuesday, April 14th. The stock was sold at an average price of $41.29, for a total transaction of $1,352,247.50. Following the sale, the director directly owned 37,500 shares of the company's
Travere Therapeutics secured full FDA approval for Filspari in FSGS, expanding its rare kidney disease franchise and driving a 37% stock surge. The FSGS approval increases TVTX's U.S. addressable market by 30,000 patients, supporting a multi-year revenue and earnings inflection not yet fully reflected in estimates. Filspari's unique, non-immunosuppressive mechanism and first-mover status in FSGS position TVTX for…
Travere Therapeutics stock jumps 37% after the FDA expands Filspari's use to a second rare kidney disease, boosting its market reach and treatment potential.
Travere (TVTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for TVTX.
U.S. House Trading
No House trades found for TVTX.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.